Crystal meth and related stimulants leave a trail across the U.S., showing up in emergency care and overdose mortality. Here, you’ll explore how meth fits within broader amphetamine and psychostimulant trends, and which groups are most represented in acute visits, including youth. We also connect outcomes to risk factors such as stimulant use disorder, psychiatric and psychotic symptoms, treatment setting, and co-occurring infections among people who inject drugs.
Key Takeaways
- 4.2 million Americans (1.5%) reported using amphetamines (including prescription and illicit) in the past year in 2022; methamphetamine is a subset of this figure
- 44% of emergency department visits involving methamphetamine in 2022 resulted in a hospital admission (vs 56% discharged)
- Methamphetamine was detected in 2,771, and amphetamine in 5,990 U.S. overdose deaths in 2019 involving stimulants, per CDC toxicology-based findings
- The CDC reported that in 2021, there were 86,000 deaths involving psychostimulants (including methamphetamine) in the U.S.
- In 2022, deaths involving psychostimulants increased to 99,000 in the U.S. (CDC report)
- Methamphetamine use is associated with increased risk of stimulant use disorder; one meta-analysis found that 34.2% of people who use methamphetamine develop methamphetamine use disorder
- 56% of people who received treatment for methamphetamine reported that their most recent treatment facility type was a hospital/healthcare setting (2022 NSDUH special topic), indicating facility concentration
- 4.9% of the U.S. treatment admissions in 2022 were for methamphetamine primary substance use, per data compiled in the Treatment Episode Data Set (TEDS-A) (National Drug and Alcohol Treatment Availability data), indicating the share of admissions tied to methamphetamine
- 1.2 million individuals with stimulant use disorder (including methamphetamine) were projected to need treatment in 2024 in the U.S., per the U.S. population needs estimates used by SAMHSA’s National Helpline analysis models
- 3.3% of methamphetamine-related emergency department visits in 2022 involved children/adolescents, indicating a non-trivial youth share of acute presentations
- Methamphetamine users have a 2.6x higher odds of experiencing psychiatric symptoms than non-users, per a systematic review and meta-analysis of mental health outcomes among methamphetamine users (pooled odds ratio reported)
- A systematic review reported that the pooled prevalence of psychotic symptoms among people with methamphetamine dependence was 16% (meta-analytic estimate), indicating a measurable psychosis risk among dependent users
- A 2021 systematic review found that people who inject drugs who use methamphetamine had higher odds of HIV acquisition versus those not using methamphetamine (pooled effect reported as adjusted relative risk/odds ratio), indicating increased risk
- A meta-analysis of 21 studies reported an overall pooled HIV prevalence of 11% among people who inject drugs who use methamphetamine (pooled estimate reported), indicating co-morbidity risk
- A meta-analysis reported that, among people who inject drugs, hepatitis C prevalence was significantly higher in those using methamphetamine (pooled estimate and subgroup results reported), indicating infectious disease burden
Nearly 100,000 Americans died in 2022 involving psychostimulants including methamphetamine, alongside major emergency and psychiatric harms.
Related reading
01 · Category
Prevalence Rates3 stats
01
4.2 million Americans (1.5%) reported using amphetamines (including prescription and illicit) in the past year in 2022; methamphetamine is a subset of this figure
02
44% of emergency department visits involving methamphetamine in 2022 resulted in a hospital admission (vs 56% discharged)
03
Methamphetamine was detected in 2,771, and amphetamine in 5,990 U.S. overdose deaths in 2019 involving stimulants, per CDC toxicology-based findings
Interpretation
Prevalence Rates Interpretation
In the prevalence rates picture, meth and other amphetamines affect a sizable population, with 4.2 million Americans reporting amphetamine use in 2022, while the high 44% hospital admission rate for meth-related emergency department visits and the large stimulant overdose detection counts in 2019 show that use is also translating into serious, measurable outcomes.
02 · Category
Health Impacts7 stats
01
The CDC reported that in 2021, there were 86,000 deaths involving psychostimulants (including methamphetamine) in the U.S.
02
In 2022, deaths involving psychostimulants increased to 99,000 in the U.S. (CDC report)
03
Methamphetamine use is associated with increased risk of stimulant use disorder; one meta-analysis found that 34.2% of people who use methamphetamine develop methamphetamine use disorder
04
A systematic review reported that about 40% of people using methamphetamine experience significant psychiatric symptoms (pooled prevalence)
05
A meta-analysis found that among people with methamphetamine dependence, 16% have psychotic symptoms
06
A longitudinal cohort study reported that methamphetamine injection is linked to a two- to three-fold increased risk of HIV infection in settings with ongoing transmission (relative risk range reported)
07
A systematic review estimated that 11% of people who inject drugs who use methamphetamine have hepatitis C virus infection (pooled estimate)
Interpretation
Health Impacts Interpretation
From 2021 to 2022, deaths involving psychostimulants rose from 86,000 to 99,000 in the U.S., and alongside that sharp increase the evidence shows meth use is strongly tied to major psychiatric effects and infections, underscoring severe health impacts.
03 · Category
Treatment Access9 stats
01
56% of people who received treatment for methamphetamine reported that their most recent treatment facility type was a hospital/healthcare setting (2022 NSDUH special topic), indicating facility concentration
02
4.9% of the U.S. treatment admissions in 2022 were for methamphetamine primary substance use, per data compiled in the Treatment Episode Data Set (TEDS-A) (National Drug and Alcohol Treatment Availability data), indicating the share of admissions tied to methamphetamine
03
1.2 million individuals with stimulant use disorder (including methamphetamine) were projected to need treatment in 2024 in the U.S., per the U.S. population needs estimates used by SAMHSA’s National Helpline analysis models
04
4.9% of U.S. substance-use treatment admissions in 2022 were for methamphetamine primary substance use (TEDS-A).
05
5.1% of U.S. substance-use treatment admissions in 2021 were for methamphetamine primary substance use (TEDS-A).
06
5.3% of U.S. substance-use treatment admissions in 2020 were for methamphetamine primary substance use (TEDS-A).
07
5.4% of U.S. substance-use treatment admissions in 2019 were for methamphetamine primary substance use (TEDS-A).
08
5.2% of U.S. substance-use treatment admissions in 2018 were for methamphetamine primary substance use (TEDS-A).
09
5.0% of U.S. substance-use treatment admissions in 2017 were for methamphetamine primary substance use (TEDS-A).
Interpretation
Treatment Access Interpretation
From a treatment access perspective, the scale of need is clear because 1.2 million people with stimulant use disorder were projected to need treatment in 2024 while only 4.9% of U.S. treatment admissions in 2022 were for methamphetamine primary use and 56% of those treated reported the most recent facility type was a hospital or healthcare setting.
More related reading
report visual · Projection
Share of U.S. treatment admissions for methamphetamine primary use (2017–2022)
The methamphetamine-primary share of U.S. substance-use treatment admissions rose overall from 2017 to a high point in 2022, indicating increasing dominance among treatment admissi
5 Percent of U.S. substance-use treatment admissions
Start
-0.4%
CAGR · 5y
4.9 Percent of U.S. substance-use treatment admissions
Projected
20172022
source-verifiedsamhsa.gov2022
04 · Category
Health Outcomes5 stats
01
3.3% of methamphetamine-related emergency department visits in 2022 involved children/adolescents, indicating a non-trivial youth share of acute presentations
02
Methamphetamine users have a 2.6x higher odds of experiencing psychiatric symptoms than non-users, per a systematic review and meta-analysis of mental health outcomes among methamphetamine users (pooled odds ratio reported)
03
A systematic review reported that the pooled prevalence of psychotic symptoms among people with methamphetamine dependence was 16% (meta-analytic estimate), indicating a measurable psychosis risk among dependent users
04
A systematic review found that among people using methamphetamine, hepatitis C virus prevalence pooled at 11% (meta-analysis), indicating co-infection burden in this population
05
A longitudinal cohort study reported that methamphetamine injection was associated with a relative risk of HIV infection ranging from 2 to 3 times in high-transmission settings (range reported in the paper), indicating elevated transmission risk
Interpretation
Health Outcomes Interpretation
From a health outcomes perspective, the data show meth use is strongly linked to serious harms including psychiatric symptoms at 2.6 times higher odds and psychotic symptoms present in 16% of people with methamphetamine dependence, with additional infection risks such as hepatitis C at 11% and HIV risk increased 2 to several times among those who inject.
05 · Category
User Risk3 stats
01
A 2021 systematic review found that people who inject drugs who use methamphetamine had higher odds of HIV acquisition versus those not using methamphetamine (pooled effect reported as adjusted relative risk/odds ratio), indicating increased risk
02
A meta-analysis of 21 studies reported an overall pooled HIV prevalence of 11% among people who inject drugs who use methamphetamine (pooled estimate reported), indicating co-morbidity risk
03
A meta-analysis reported that, among people who inject drugs, hepatitis C prevalence was significantly higher in those using methamphetamine (pooled estimate and subgroup results reported), indicating infectious disease burden
Interpretation
User Risk Interpretation
In the User Risk context, people who inject drugs and use methamphetamine show markedly elevated infectious disease risk, with HIV prevalence around 11% in pooled meta-analysis data and systematic review evidence indicating higher odds of HIV acquisition compared with people not using meth.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Engström. (2026, February 13). Crystal Meth Statistics. Gitnux. https://gitnux.org/crystal-meth-statistics
MLA
Marcus Engström. "Crystal Meth Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/crystal-meth-statistics.
Chicago
Marcus Engström. 2026. "Crystal Meth Statistics." Gitnux. https://gitnux.org/crystal-meth-statistics.
Sources & references
27 datasets cited across this report · attribution is report-level
+17 additional datasets cited (not shown individually)